NPS Pharmaceuticals, Inc. Receives Notice From FDA of Advisory Committee Meeting for Gattex® (teduglutide)

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex® (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA is December 30, 2012.